Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Mol Pharm. 2016 May 26;13(6):2070–2083. doi: 10.1021/acs.molpharmaceut.6b00205

Figure 7.

Figure 7

Viability of A2780/CDDP, ES2 and IGROV1 ovarian cancer cells after treatment with media (control), DJ-1 siRNA-loaded nanoplatform and combinatorial therapy (Combo). Means ± SD are shown. *p < 0.05 when compared with cancer cells treated with media.